Abeona Therapeutics Inc. (ABEO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.60
- As of
Kresmion compiles this page from ABEO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ABEONA THERAPEUTICS INC. (ABEO): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-09.
See the full ABEO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ABEO on one page. Preview it with sample data, then open it live with a free account.
Preview the ABEO dossierActive events for ABEO
- mediumEarnings above estimates
Q3-2026: Beat consensus by 48.6%, EPS $-0.08 vs $-0.1556 estimate
- high13F: funds added
3 tracked funds increased ABEO this 2026Q2, institutional consensus
- mediumTrend spike
ABEONA THERAPEUTICS INC. search volume spiked +100 pts, unusual interest
- high13F: large increase
CITADEL ADVISORS LLC added +209% to ABEO (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 50% of ABEO (2026Q2)
FREE, NO ACCOUNT
Every event on ABEO, as it fires
You are seeing 5 of 7 events recorded on ABEO since 2026-08-13.
The five above landed across 4 days. The other 2 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, ABEO
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on ABEO
ABEO against its peers
ABEO's operating margin of -1536.9% ranks in the 42nd percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ABEO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 5.8M USD | 2.9M USD | 54 | 13 |
| Gross margin | 73.7% | n/a | n/a | 3 |
| Operating margin | -1536.9% | -677.1% | 42 | 12 |
| Net margin | 1223.1% | -488.2% | 88 | 12 |
| Return on equity | 44.7% | -42.2% | 97 | 17 |
| P / E | 2.6x | n/a | n/a | 2 |
| 1 year | -38.1% | -32.5% | 43 | 19 |
Peers (22): UPB, YARW, ARMP, ALXO, HUMA, FATE, TARA, IPHA, NTHI, MENS, MGNX, MSLE, CMPX, SION, ORMP, STRO, CNTN, NAGE, ZNTL, PYPD, LENZ, IVVD. Left out: VRXA (no annual filing), RNA (no annual filing), SCNLD (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ABEO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ABEO on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ABEO in the last 180 days.
Upstream: SEC EDGAR filings for ABEO
Kresmion, "ABEONA THERAPEUTICS INC. (ABEO) institutional holdings and SEC filings", data as of 2026-11-12, https://kresmion.com/research/ABEO. Upstream data: SEC EDGAR filings for ABEO.
Link to this data (HTML):
<a href="https://kresmion.com/research/ABEO">ABEONA THERAPEUTICS INC. (ABEO) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ABEO on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ABEO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.